| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The classification of glomerulonephritis in systemic lupus erythematosus revisited.
|
J Am Soc Nephrol
|
2004
|
7.38
|
|
2
|
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
|
J Am Soc Nephrol
|
2009
|
5.02
|
|
3
|
The classification of glomerulonephritis in systemic lupus erythematosus revisited.
|
Kidney Int
|
2004
|
4.77
|
|
4
|
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
|
N Engl J Med
|
2011
|
4.08
|
|
5
|
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.
|
Arthritis Rheum
|
2013
|
4.02
|
|
6
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2011
|
3.81
|
|
7
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
|
Arthritis Rheum
|
2009
|
3.34
|
|
8
|
Novel evidence-based systemic lupus erythematosus responder index.
|
Arthritis Rheum
|
2009
|
2.58
|
|
9
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
|
Arthritis Res Ther
|
2008
|
2.15
|
|
10
|
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
|
Ann Rheum Dis
|
2012
|
1.85
|
|
11
|
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
|
Arthritis Rheum
|
2002
|
1.70
|
|
12
|
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
|
Rheumatology (Oxford)
|
2009
|
1.48
|
|
13
|
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
|
J Rheumatol
|
2005
|
1.37
|
|
14
|
Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
|
Clin J Am Soc Nephrol
|
2012
|
1.25
|
|
15
|
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
|
Kidney Int
|
2009
|
1.08
|
|
16
|
Lymphoma risk in systemic lupus: effects of disease activity versus treatment.
|
Ann Rheum Dis
|
2013
|
1.03
|
|
17
|
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
|
Ann Rheum Dis
|
2012
|
1.02
|
|
18
|
Use of mycophenolate mofetil in autoimmune and renal diseases.
|
Transplantation
|
2005
|
1.01
|
|
19
|
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus.
|
Arthritis Rheum
|
2002
|
1.01
|
|
20
|
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
|
Arthritis Rheum
|
2004
|
1.01
|
|
21
|
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
1.00
|
|
22
|
Familiality and co-occurrence of clinical features of systemic lupus erythematosus.
|
Arthritis Rheum
|
2002
|
0.95
|
|
23
|
Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.
|
Rheum Dis Clin North Am
|
2006
|
0.94
|
|
24
|
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response.
|
Arthritis Rheum
|
2008
|
0.94
|
|
25
|
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.
|
Arthritis Rheum
|
2008
|
0.94
|
|
26
|
Non-lymphoma hematological malignancies in systemic lupus erythematosus.
|
Oncology
|
2013
|
0.83
|
|
27
|
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
|
J Rheumatol
|
2008
|
0.82
|
|
28
|
Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus.
|
Rheum Dis Clin North Am
|
2010
|
0.78
|
|
29
|
Pulmonary manifestations of systemic lupus erythematosus.
|
Semin Respir Crit Care Med
|
2007
|
0.78
|
|
30
|
Systemic lupus erythematosus (SLE): Trials and issues.
|
Discov Med
|
2004
|
0.75
|
|
31
|
[Treatment of lupus nephritis].
|
Reumatol Clin
|
2008
|
0.75
|